

This report presents the recommendations of a WHO Expert Committee commissioned to coordinate activities leading to the adoption of international recommendations for the production and control of vaccines and other biologicals and the establishment of international biological reference materials.

The report starts with a discussion of general issues brought to the attention of the Committee and provides information on the status and development of reference materials for various antibodies, antigens, blood products and related substances, cytokines, growth factors, and endocrinological substances. The second part of the report, of particular relevance to manufacturers and national regulatory authorities, contains WHO recommendations and guidelines on human papillomavirus vaccines; meningococcal A conjugate vaccines; and stability evaluation of vaccines.

Also included are a list of recommendations, guidelines and other documents for biological substances used in medicine, and of international standards and reference reagent for biological substances.

WHO Expert Committee on Biological Standardization

Fifty-seventh report



The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences.

To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The *WHO Technical Report Series* makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO.

For further information, please contact WHO Press, World Health Organization; 1211 Geneva 27, Switzerland; www.who.int/bookorders; tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int.

SELECTED WHO PUBLICATIONS OF RELATED INTEREST

WHO Expert Committee on Biological Standardization

Fifty-sixth report.

WHO Technical Report Series, No. 941, 2007 (340 pages)

web site www.who.int/biologicals

WHO Expert Committee on Biological Standardization

Fifty-fifth report.

WHO Technical Report Series, No. 932, 2006 (137 pages)

WHO Expert Committee on Biological Standardization

Fifty-fourth report.

WHO Technical Report Series, No. 927, 2005 (154 pages)

WHO Expert Committee on Biological Standardization

Fifty-third report.

WHO Technical Report Series, No. 926, 2004 (109 pages)

Further information on these and other WHO publications can be obtained from
WHO Press, World Health Organization ■ 1211 Geneva 27, Switzerland ■ www.who.int/bookorders
tel.: +41 22 791 3264; **fax:** +41 22 791 4857; **e-mail:** bookorders@who.int

W H O T e c h n i c a l R e p o r t S e r i e s
9 6 2

WHO Expert Committee on Biological Standardization

Fifty-seventh report

*This report contains the collective views of an international group of experts and
does not necessarily represent the decisions or the stated policy of the World Health Organization*



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Fifty-seventh report/WHO Expert Committee on Biological Standardization.

(WHO technical report series ; no. 962)

1. Biological products - standards. 2. Vaccines - standards. 3. Reference standards.
4. Guidelines. I.World Health Organization. II.WHO Expert Committee on Biological
Standardization (2006: Geneva, Switzerland). III.Series.

ISBN 978 92 4 120962 5
ISSN 0512-3054

(NLM classification: QW 800)

©World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of the World Health Organization.

Design: WHP (Sophie Guetaneh Aguetant)

Layout: Interligar (<http://www.interligar.com.br>)

Printed in Italy

Contents

WHO Expert Committee on Biological Standardization	v
Introduction	1
General	3
Developments in biological standardization	3
Coordination with other standards-setting bodies for biological reference preparations: reports from international groups	11
Stability of WHO biological reference preparations: report of a WHO Working Group	12
Improving access to WHO biological standards: report from WHO Regional Office for South-East Asia	14
Development of assessment tools to monitor the implementation of international standards	15
International Nonproprietary Names for biotechnology products	16
WHO Blood Regulators Network	18
International recommendations, guidelines, and other matters related to the manufacture and quality control of biologicals	19
Guidelines for assuring the quality, safety and efficacy of human papillomavirus vaccines	19
Guidelines for assuring the quality, safety and efficacy of meningococcal A conjugate vaccines	20
Guidelines for stability evaluation of vaccines	21
Regulatory preparedness for pandemic influenza vaccines	21
Expedited approval of vaccines used in national immunization programmes and procured through United Nations agencies	23
Acceptability of cell substrates	24
Proposed development of new human diploid fibroblast cell bank for manufacture of biological medicines	24
Regulatory expectations for evaluation of flavivirus vaccines	25
In vitro diagnostic devices	26
Quality, safety and efficacy of antivenom sera	27
Global measurement standards	29
Antigens and related substances	29
Pertussis vaccine (whole cell) – fourth International Standard	29
Smallpox vaccine – second International Standard	30
Poliovirus, Sabin, type 3 – International Standard for the polio neurovirulence test	30
Anti-poliovirus serum, types, 1, 2 and 3 – third International Standard	31
Anti-measles serum – third International Standard	32
Blood products and related substances	35
Anti-A and Anti-B, blood group reagents	35
Blood coagulation factor XIII, plasma	35
Alpha-1-antitrypsin – first International Standard	36
Protein S, plasma, human – second International Standard	37
Protein C, plasma, human – second International Standard	39

Blood coagulation factor VIII inhibitor antibody	40
Vitamin B12 and serum folate	40
Fibrinolysis	40
Cytokines, growth factors and endocrinological substances	43
Thyroid-stimulating hormone, recombinant, human, for bioassay – first International Standard	43
Interleukin-17 – WHO Reference Reagent	43
Interleukin-18 – WHO Reference Reagent	44
Diagnostic reagents	47
Hepatitis B DNA for nucleic acid amplification test assays – second International Standard	47
<i>Plasmodium falciparum</i> , in whole blood, for nucleic acid amplification test assays – first International Standard	47
Anti-human immunodeficiency virus tests – first International Reference Panel	48
Anti-human platelet antigen 3a, for minimum potency estimates – first International Standard	49
Annex 1	
Guidelines for assuring the quality, safety and efficacy of human papillomavirus vaccines	51
Annex 2	
Guidelines for assuring the quality, safety and efficacy of meningococcal A conjugate vaccines	115
Annex 3	
Guidelines for stability evaluation of vaccines	173
Annex 4	
Biological substances: International Standards and Reference Reagents	201
Annex 5	
Recommendations and guidelines for biological substances used in medicine and other documents	203

WHO Expert Committee on Biological Standardization

Geneva, 23–27 October 2006

Members

Prof. W.G. van Aken, Amstelveen, the Netherlands

Dr R. Dobbelaer, Head, Biological Standardization, Louis Pasteur Scientific Institute of Public Health, Brussels, Belgium (Chairman)

Dr F. Fuchs, Director – Lyon Site, French Agency for Safety of Health Products, Lyon, France

Mrs T. Jivapaisarnpong, Director, Division of Biological Products, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand (Vice-Chair)

Dr H. Klein, National Institutes of Health, Warren G. Magnuson Clinical Center, Department of Transfusion Medicine, Bethesda, MD, USA

Dr P. Minor, Head, Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Herts., England

Dr A. Tahlan, Joint Director & Government Analyst, Central Drugs Laboratory, Central Research Institute, Kasauli, India (Rapporteur)

Professor Hongzhang Yin, Division of Biological Products, State Food and Drug Administration, Beijing, China

Professor G.N. Vyas, Department of Laboratory Medicine, University of California, San Francisco, CA, USA

Representatives from other organizations

Council of Europe, European Directorate for the Quality of Medicine

Mr J.M. Spieser, European Directorate for the Quality of Medicines, European Pharmacopoeia Commission, Strasbourg, France

Dr K.H. Buchheit, European Directorate for the Quality of Medicines, European Pharmacopoeia Commission, Strasbourg, France

Developing Country Vaccine Manufacturers' Network

Dr S. Jadhav, Serum Institute of India Ltd, Pune, India

European Diagnostic Manufacturers Association

Dr J. Diment, Scientific Affairs, Europe, Asia-Pacific and Middle East, Ortho-Clinical Diagnostics, Johnson & Johnson, High Wycombe, Bucks., England

International Association of Biologicals

Dr A. Eshkol, Sero International SA, Geneva, Switzerland

International Bureau of Weight and Measures

Dr Robert Wielgosz, Head of Chemistry Section, International Bureau of Weights and Measures, Sèvres, France

International Federation of Clinical Chemistry and Laboratory Medicine

Dr J.C. Forest, Director of Research, Centre hospitalier universitaire de Québec, Quebec City, Canada

International Federation of Pharmaceutical Manufacturers Associations

Dr C.Y. Chan, Senior Medical Director, International Medical Affairs & Health Policy, Merck Vaccine Division, Merck & Co. Inc., West Point, PA, USA

Dr T.L. Schofield, Senior Director, Vaccine Biometric Research, Merck Research Laboratories, West Point, PA, USA

Dr A. Sabouraud, Responsible Pharmacist, Quality Control of Development Products, Sanofi Pasteur SA, Marcy l'Etoile, France

Dr M. Dûchene, Head, Product Life Cycle Management, GlaxoSmithKline Biologicals, Rixensart, Belgium

International Plasma Fractionation Association

Dr D. Armstrong, National Bioproducts Institute, Pinetown, South Africa

International Organization for Standardization

Mr T. Hancox, Technical Programme Manager, Standards Department, ISO, Geneva, Switzerland

International Society of Blood Transfusion

Dr P. Strengers, Amsterdam, the Netherlands

International Society on Thrombosis and Haemostasis

Dr E. Gray, National Institute for Biological Standards and Control, Potters Bar, Herts., England

PATH Europe

Dr S. Viviani, Vaccine Development Manager, Meningitis Vaccine Project, Ferney-Voltaire, France

Plasma Protein Therapeutics Association

Dr I. von Hoegen, Director, Regulatory Affairs, PPTA Europe, Brussels, Belgium

United States Pharmacopoeia

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>